Jessica L Montoya1, Jordan Cattie1, Erin Morgan2, Steven Paul Woods2, Mariana Cherner2, David J Moore2, J Hampton Atkinson2,3, Igor Grant2. 1. a Clinical Psychology, San Diego State University/University of California, San Diego Joint Doctoral Program , San Diego , CA , USA. 2. b Translational Methamphetamine AIDS Research Center, Department of Psychiatry , School of Medicine, University of California, San Diego , La Jolla , CA , USA. 3. c VA San Diego Healthcare System , San Diego , CA , USA.
Abstract
BACKGROUND: Characterizing methamphetamine use in relation to age, HIV serostatus and seroconversion is pertinent given the increasingly older age of the population with HIV and the intertwined epidemics of methamphetamine use and HIV. OBJECTIVES: Study aims were to investigate whether (i) methamphetamine use differs by age and HIV serostatus, and (ii) receiving an HIV diagnosis impacts methamphetamine use among younger and older persons with HIV. METHODS: This study examined methamphetamine use characteristics among 217 individuals with a lifetime methamphetamine dependence diagnosis who completed an in-person study assessment. RESULTS: Multivariable regressions revealed that HIV serostatus uniquely attenuates methamphetamine use, such that persons with HIV report a smaller cumulative quantity (β = -0.16, p = 0.01) and a fewer number of days (β = -0.18, p = 0.004) of methamphetamine use than persons without HIV. Among the HIV+ sample, all participants persisted in methamphetamine use after receiving an HIV diagnosis, with about 20% initiating use after seroconversion. Repeated measures analysis of variance indicated that density of methamphetamine use (i.e. grams per day used) was greater among the younger, relative to the older, HIV+ group (p = 0.02), and increased for both age groups following seroconversion (p < 0.001). CONCLUSION: These analyses indicate that although HIV serostatus may attenuate methamphetamine use behaviors, many people with HIV initiate, or persist in, methamphetamine use after receiving an HIV diagnosis. These findings raise the question of whether tailoring of prevention and intervention strategies might reduce the impact of methamphetamine and HIV across the age continuum.
BACKGROUND: Characterizing methamphetamine use in relation to age, HIV serostatus and seroconversion is pertinent given the increasingly older age of the population with HIV and the intertwined epidemics of methamphetamine use and HIV. OBJECTIVES: Study aims were to investigate whether (i) methamphetamine use differs by age and HIV serostatus, and (ii) receiving an HIV diagnosis impacts methamphetamine use among younger and older persons with HIV. METHODS: This study examined methamphetamine use characteristics among 217 individuals with a lifetime methamphetamine dependence diagnosis who completed an in-person study assessment. RESULTS: Multivariable regressions revealed that HIV serostatus uniquely attenuates methamphetamine use, such that persons with HIV report a smaller cumulative quantity (β = -0.16, p = 0.01) and a fewer number of days (β = -0.18, p = 0.004) of methamphetamine use than persons without HIV. Among the HIV+ sample, all participants persisted in methamphetamine use after receiving an HIV diagnosis, with about 20% initiating use after seroconversion. Repeated measures analysis of variance indicated that density of methamphetamine use (i.e. grams per day used) was greater among the younger, relative to the older, HIV+ group (p = 0.02), and increased for both age groups following seroconversion (p < 0.001). CONCLUSION: These analyses indicate that although HIV serostatus may attenuate methamphetamine use behaviors, many people with HIV initiate, or persist in, methamphetamine use after receiving an HIV diagnosis. These findings raise the question of whether tailoring of prevention and intervention strategies might reduce the impact of methamphetamine and HIV across the age continuum.
Entities:
Keywords:
HIV risk behavior; HIV/AIDS; Methamphetamine; age; stimulant
Authors: Titia Heijman; Ronald B Geskus; Udi Davidovich; Roel A Coutinho; Maria Prins; Ineke G Stolte Journal: AIDS Date: 2012-02-20 Impact factor: 4.177
Authors: Terry R Barclay; Charles H Hinkin; Steven A Castellon; Karen I Mason; Matthew J Reinhard; Sarah D Marion; Andrew J Levine; Ramani S Durvasula Journal: Health Psychol Date: 2007-01 Impact factor: 4.267
Authors: David J Moore; Kaitlin Blackstone; Steven Paul Woods; Ronald J Ellis; J Hampton Atkinson; Robert K Heaton; Igor Grant Journal: AIDS Care Date: 2012-04-24
Authors: Sin How Lim; David Ostrow; Ron Stall; Joan Chmiel; Amy Herrick; Steve Shoptaw; Uyen Kao; Adam Carrico; Michael Plankey Journal: AIDS Behav Date: 2012-01
Authors: Pamina M Gorbach; Robert E Weiss; Robin Jeffries; Marjan Javanbakht; Lydia N Drumright; Eric S Daar; Susan J Little Journal: J Acquir Immune Defic Syndr Date: 2011-02-01 Impact factor: 3.731
Authors: Grant N Colfax; Susan P Buchbinder; Peter G A Cornelisse; Eric Vittinghoff; Kenneth Mayer; Connie Celum Journal: AIDS Date: 2002-07-26 Impact factor: 4.177
Authors: Virawudh Soontornniyomkij; James P Kesby; Erin E Morgan; Amanda Bischoff-Grethe; Arpi Minassian; Gregory G Brown; Igor Grant Journal: J Neuroimmune Pharmacol Date: 2016-08-02 Impact factor: 4.147
Authors: Emily W Paolillo; Rowan Saloner; Jessica L Montoya; Laura M Campbell; Elizabeth C Pasipanodya; Jennifer E Iudicello; Raeanne C Moore; Scott L Letendre; Dilip V Jeste; David J Moore Journal: AIDS Res Hum Retroviruses Date: 2019-08-12 Impact factor: 2.205
Authors: Nina Pocuca; Jared W Young; David A MacQueen; Scott Letendre; Robert K Heaton; Mark A Geyer; William Perry; Igor Grant; Arpi Minassian Journal: Drug Alcohol Depend Date: 2020-08-22 Impact factor: 4.492
Authors: Rowan Saloner; Erin E Morgan; Mariam A Hussain; David J Moore; Robert K Heaton; Mariana Cherner; Igor Grant; Jennifer E Iudicello Journal: J Neurovirol Date: 2022-01-03 Impact factor: 3.739